Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies

Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas. Forty-six patients with locally advanced or metastatic soft-tissue sarcomas were incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Leyvraz, S, Herrmann, R, Guillou, L, Honegger, H P, Christinat, A, Fey, M F, Sessa, C, Wernli, M, Cerny, T, Dietrich, D, Pestalozzi, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360595/
https://www.ncbi.nlm.nih.gov/pubmed/17031396
http://dx.doi.org/10.1038/sj.bjc.6603420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360595/
https://www.ncbi.nlm.nih.gov/pubmed/17031396
http://dx.doi.org/10.1038/sj.bjc.6603420

Ejemplares similares